Anti-Human/Mouse Integrin β7 – Purified in vivo PLATINUM™ Functional Grade
Pricing & Details
≥ 5.0 mg/ml
<0.5 EU/mg as determined by the LAL method
≥98% monomer by analytical SEC
>95% by SDS Page
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this FIB504 antibody for staining cells in flow cytometry is ≤0.5 µg per 106 cells in a volume of 100 μl or 100 μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
Other Applications Reported In Literature ?
B This antibody has been reported to block beta7 integrin mediated cell adhesion for In vitro and In vivo studies.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Clone FIB504 recognizes an epitope on human/mouse integrin β7.
Integrin α4β7 is expressed on subsets of peripheral lymphocytes, thymocytes, and bone marrow progenitors. The αEβ7 integrin is expressed on mucosal T cells, including intraepithelial T lymphocytes (IELs) and lamina propria T cells, subsets of dendritic cells, and regulatory T cells (Tregs)8.
Integrin β7 antibody, clone FIB504, recognizes integrin β7, a 130 kDa membrane glycoprotein of the Ig superfamily. Integrin β7 forms heterodimers with both the α4 (CD49d) and aE (CD103) integrins. α4β7 integrin is expressed on subsets of peripheral lymphocytes, thymocytes, and bone marrow progenitors1,2. It mediates adhesion to mucosal endothelial cells, promoting leukocyte transendothelial migration through interactions with mucosal addressin cell adhesion molecule-1 (MAdCAM-1)3,4. The αEβ7 integrin is expressed on mucosal T cells, including intraepithelial T lymphocytes (IELs) and lamina propria T cells5,6, subsets of dendritic cells7, and regulatory T cells (Tregs)8. It facilitates retention in the gut epithelial layer via interactions with E-cadherin9. Anti-β7 antibodies block both the homing to and retention in the gut of pathogenic T cells10 and are currently under evaluation in a phase 3 clinical trial to treat inflammatory bowel disease11.
CD49d/β7: VCAM-1 (CD106), MAdCAM-1 and fibronectin; CD103/β7: E-cadherin
Lymphocyte adhesion, hematopoietic progenitor cells migration
NCBI Gene Bank ID
References & Citations
1. Andrew DP, et al. (1996) Eur J Immunol. 26(4):897-905
2. Murakami JL, et al. (2016) Stem Cells Dev. 25(1):18-26
3. Hu MC, et al. (1992) Proc Natl Acad Sci USA. 89(17):8254-8
4. Hamann A, et al. (1994) J Immunol. 152(7):3282-93
5. Hadley GA Higgins JM. (2014) Adv Exp Med Biol. 819:97–110
6. Farstad IN., et al. (1996) Immunology. 89:227–37
7. Jaensson E., et al. (2008) J Exp Med. 205:2139–49
8. Allez M, et al. (2002) Gastroenterology. 123(5):1516-26
9. Schön MP, et al. (1999) J Immunol. 162(11):6641-9
10. Stefanich EG, et al. (2011) Br J Pharmacol. 162(8):1855-1870
11. Smids C, et al. (2017) J Crohns Colitis. 11(4):500-508